Skip to main content
OpenTrials
Completed

NCT Number: NCT03882008

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

The primary objective of this study is to evaluate if baseline levels of T cell associated biomarkers predict efficacy of abatacept during 24 weeks of treatment in patients with moderate to severe active Rheumatoid Arthritis (RA) who have had an inadequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Washington

Seattle, Washington, 98195, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant, non-nursing female
  • Age 18 years or greater
  • Body weight less than or equal to 120 kg
  • Classification of Rheumatoid Arthritis according to the 1987 ACR criteria or 2010 ACR/EULAR criteria
  • Symptoms of Rheumatoid Arthritis present for at least 3 months and less that 10 years prior to Screening.
  • Clinical Disease Activity Index (CDAI) greater than or equal to 16, corresponding to moderate to severe disease activity.
  • Patients taking oral DMARDs must be on stable doses of DMARDs for at least 4 weeks prior to Abatacept initiation
  • Treatment within the past year with either methotrexate, leflunomide, hydroxychloroquine and/or sulfasalazine for greater than or equal to 8 weeks.
  • Patients who have received one prior Tumor necrosis factor (TNF) inhibitor must have discontinued etanercept, infliximab, adalimumab, certolizumab, or golimumab for at least 6 months prior to screening.
  • Patients taking oral corticosteroids, the dose must be less than or equal to 5mg per day (prednisone or equivalent)
  • Females of child bearing potential and males with female partners of child bearing potential may participate in this study only if using a reliable means of contraception

Exclusion criteria

  • Previous treatment with Abatacept (Orencia)
  • Previous treatment with rituximab, tocilizumab, tofacitinib, sarilumab, or anakinra
  • Previous treatment with IV immunoglobulin, plasmapheresis, or alkylating agents such as cyclophosphamide
  • Intraarticular or parenteral corticosteroids within 4 weeks of screening
  • Rheumatic autoimmune disease other than Rheumatoid Arthritis, including Systemic Lupus Erythematosus, primary Sjogren syndrome, spondyloarthritis, systemic sclerosis, dermatomyositis, mixed connective tissue disease, or vasculitis
  • Non-rheumatic auto-immune disease including inflammatory bowel disease, psoriasis, multiple sclerosis
  • Recurrent or chronic bacterial, viral, fungal, mycobacterial, or other infections including Human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, latent tuberculosis (TB) (TB not adequately treated)
  • Primary or secondary immunodeficiency
  • Current, uncontrolled renal, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease
  • History of malignancy within 10 years prior to screening, except for appropriately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma
  • History of alcohol, drug, or chemical abuse within 1 year prior to screening
  • Laboratory exclusion criteria at screening including:
  • estimated glomerular filtration rate (eGFR) <30ml/min
  • Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >1.5 times upper limit of normal
  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery during the study
  • Immunization with a live/attenuated vaccine within 4 weeks prior to screening
  • Pregnant or nursing women, or women of child bearing potential who plan to become pregnant prior to 14 weeks after the last dose of abatacept treatment
  • Patients of reproductive potential not willing to use an effective method of contraception
  • Prisoners, or subjects who are compulsory detained

Treatment and study plan

Abatacept

Drug

All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks

Other names: Orencia

Primary outcomes

  1. Number of Participants With American College of Rheumatology (ACR) 20 Response at Week 14

    Time frame: 14 Weeks

    Baseline levels of T cell-associated biomarkers predict ACR20 response (improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, pain, functional ability measure, erythrocyte sedimentation rate (ESR) or C-reactive protein) with subcutaneous abatacept

Secondary outcomes

  1. Number of Participants With American College of Rheumatology (ACR) 20 Response at Week 24

    Time frame: 24 Weeks

    Baseline levels of T cell associated biomarkers predict ACR20 response (improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, pain, functional ability measure, erythrocyte sedimentation rate (ESR) or C-reactive protein) with subcutaneous abatacept

  2. Number of Participants With American College of Rheumatology (ACR) 50 Response at Week 24

    Time frame: Week 24

    Baseline levels of T cell associated biomarkers predict ACR50 response (improvement of 50% in the number of tender and number of swollen joints, and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, pain, functional ability measure, erythrocyte sedimentation rate (ESR) or C-reactive protein) with subcutaneous abatacept

  3. Number of Participants With American College of Rheumatology (ACR) 70 Response at Week 24

    Time frame: Week 24

    Baseline levels of T cell associated biomarkers predict ACR70 response (improvement of 70% in the number of tender and number of swollen joints, and a 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, pain, functional ability measure, erythrocyte sedimentation rate (ESR) or C-reactive protein) with subcutaneous abatacept

  4. Number of Participants With European League Against Rheumatism (EULAR) Good or Moderate Response at Week 24

    Time frame: Week 24

    Baseline levels of T cell associated biomarkers predict EULAR good or moderate response (disease activity index for RA generated from tender and swollen joint count, patient global assessment, ESR or C-reactive protein) with subcutaneous abatacept

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Bristol-Myers Squibb

Registry information

Official study title

Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Mar 20, 2019
Registry last updated
Jul 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.